Daien, Vincent
Eldem, Bora M.
Talks, James S.
Korobelnik, Jean-Francois
Mitchell, Paul
Finger, Robert P.
Sakamoto, Taiji
Wong, Tien Yin
Evuarherhe, Obaro
Carter, Gemma
Carrasco, Joao
Funding for this research was provided by:
Bayer
Article History
Received: 12 December 2018
Accepted: 30 August 2019
First Online: 16 October 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The authors report consulting fees, travel support and financial and non-financial support outside the submitted work: V. Daien - Alcon, Bayer, Horus, Novartis and Thea; B. M. Eldem - Alcon, Allergan Novartis, Bayer, Baush & Lomb, Ophtotech, Pfizer, Roche, Sanofi, Santen, Servier and Thea; J. S. Talks - Allergan, Bayer and Novartis; J.-F. Korobelnik - Alcon, Bayer, Baush & Lomb, Beaver Visitec, Krys, Kanghing, NanoRetina, Novartis, Roche, Thea and Zeiss; P. Mitchell - Abbott, Allergan, Bayer, Genentech, Novartis and Roche; R. P. Finger - Bayer, Novartis, Novelion, Opthea, RetinaImplant and Santen; T. Sakamoto: Alcon, Bayer, Novartis, Santen, Senju and Wakamoto; T.Y. Wong - Abbott, Allergan, Bayer, Novartis, Pfizer and Roche; O. Evuarherhe is an employee of Oxford PharmaGenesis; G. Carter is an employee of Oxford PharmaGenesis; J. Carrasco is an employee of Bayer.